Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. Summary
    ILMN   US4523271090

ILLUMINA, INC.

(ILMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/28/2021 07/29/2021 07/30/2021 08/02/2021 08/03/2021 Date
492.22(c) 491.63(c) 495.75(c) 492.99(c) 496.31 Last
390 880 488 122 497 859 424 957 195 090 Volume
+1.23% -0.12% +0.84% -0.56% +0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4 149 M - -
Net income 2021 716 M - -
Net cash position 2021 1 672 M - -
P/E ratio 2021 101x
Yield 2021 -
Sales 2022 4 622 M - -
Net income 2022 988 M - -
Net cash position 2022 2 595 M - -
P/E ratio 2022 74,4x
Yield 2022 -
Capitalization 71 977 M 71 977 M -
EV / Sales 2021 16,9x
EV / Sales 2022 15,0x
Nbr of Employees 7 825
Free-Float 74,7%
More Financials
Company
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the... 
More about the company
Ratings of Illumina, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ILLUMINA, INC.
07/28ILLUMINA : to Webcast Upcoming Investor Conference
BU
07/23ILLUMINA : EU Commission To Probe Illumina's $7.1 Billion Grail Acquisition
MT
07/23ILLUMINA : European Commission to Probe Illumina's Acquisition of Grail
MT
07/22Illumina deal for Grail could hurt innovation, EU warns
RE
07/22ILLUMINA : Pledges to Re-Acquire Healthcare Company Grail Amid EU Probe
MT
07/22ILLUMINA : is Committed to Bringing Lifesaving GRAIL Test to People Globally as ..
BU
07/22EU Opens In-Depth Investigation Into Illumina's Proposed Acquisition of Grail
DJ
07/22ILLUMINA : deal for Grail could hurt innovation, EU warns
RE
07/19ILLUMINA : Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member..
AQ
07/14Sanigen Announces Partnership with Illumina on Food Safety and Microbiology B..
CI
07/14MARKET CHATTER : EU Sets Deadline For Illumina's Concession Offers Over Grail Me..
MT
07/13ILLUMINA : to Announce Second Quarter 2021 Financial Results on Thursday, August..
BU
07/13ILLUMINA : Grail deal faces full-scale EU antitrust probe -sources
RE
07/13ILLUMINA : Barclays Adjusts Price Target on Illumina to $355 From $300, Maintain..
MT
07/05ILLUMINA, INC. : Report
CO
More news
News in other languages on ILLUMINA, INC.
07/22UE abre investigación detallada de propuesta de compra de Grail por Illumina
04/06WALL STREET STOCK EXCHANGE : Wall Street se redresse, soutenue par la tech et la..
04/06Les valeurs à suivre aujourd'hui à Wall Street Mardi 6 avril 2021
04/06ILLUMINA : le chiffre d'affaires dépassera le milliard de dollars au premier tri..
03/31EN DIRECT DES MARCHES : Capgemini, Total, Eramet, Casino, Visiomed, Bayer, Wells..
More news
Analyst Recommendations on ILLUMINA, INC.
More recommendations
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | MarketScreener
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Last Close Price 492,99 $
Average target price 423,68 $
Spread / Average Target -14,1%
EPS Revisions
Managers and Directors
Francis A. deSouza President, Chief Executive Officer & Director
Sam A. Samad Chief Financial Officer & Senior Vice President
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors